The Australian: Cancer trial results prove good medicine for biotech's stocks

Nov 17th, 2015

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

Read More

Targeted DEP™ outperforms leading treatments in ovarian cancer model

Nov 16th, 2015

Melbourne, Australia; Starpharma today announced that treatment with its novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Read More

Starpharma receives $3.4M R&D tax incentive refund

Nov 12th, 2015

Starpharma today announced it has received the anticipated $3.4M of R&D tax incentive refund related to FY15 expenditures.

Read More

Starpharma to present at Bio-Europe® conference

Nov 4th, 2015

Starpharma today announced that it will present at the Bio-Europe® conference in Munich which is being held this week. At the conference Starpharma will also be conducting partnering discussions for VivaGel® BV and DEP™ with pharmaceutical companies.

Read More

Appendix 4C - Quarterly Cashflow Report

Oct 30th, 2015

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2015.

Read More

Shareholder Update October 2015

Oct 29th, 2015

In this Issue:

› EU marketing approval granted for VivaGel® BV
› Multi-product DEP® license with AstraZeneca
› VivaGel® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Read More

Additional US Patent Granted for VivaGel® BV

Oct 14th, 2015

Starpharma today announced the granting of a patent by the US Patent Office for VivaGel® related to the prevention of recurrence of bacterial vaginosis (BV). The patent’s term is to 2032 providing an extension of seven years over granted VivaGel® patents. Additional term may also be available subject to timing of regulatory approval.

Read More

OTCQX Life Sciences Presentation

Oct 1st, 2015

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX  investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.

Read More

The Australian: Starpharma wins EU approval for VivaGel

Sep 24th, 2015

The Australian reports that "Starpharma has been granted approval to market its VivaGel BV in the European Union's 28 member countries, where more than 260 million women live. The lubricant treats bacterial vaginosis (BV), the most common vaginal infection experienced by women around the world".

Go to the article (external link)

Read More

EU Marketing Approval Granted for VivaGel® BV

Sep 24th, 2015

Starpharma today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.

Read More

The Wall Street Journal/The Australian: Australia looks to health care as a remedy for resource slump doldrums

Sep 17th, 2015

The Wall Street Journal's Rachel Pannett comments that 'Australia is taking a page from Silicon Valley's playbook as it seeks to reinvigorate its resource-dependent economy at the end of a long commodities boom, placing bets on biotechnology and digital health care'. Tax incentives for R&D have moved Australia to fourth place globally for biotechnology innovation, with a further boost expected following a change of Prime Minister from Tony Abbott to Malcolm Turnbull. Starpharma is featured in the article for its drug delivery technology and recent licensing deal with AstraZeneca.

Go to the article (external link)

Read More

The Wall Street Journal: 5 Things to know about Australia's biotech push

Sep 16th, 2015

The Wall Street Journal's Rachell Pannett provides a summary of Australia's biotech industry, highlighting Starpharma's drug delivery technology as one of Australia's 'interesting discoveries'.

Go to the article (external link)

Read More